Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ELVN
ELVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ELVN News
Helen Collins Sells 40,000 Shares of Enliven Therapeutics
2d ago
NASDAQ.COM
Enliven's CMO Exercises and Sells Stock Options for $1.2 Million
2d ago
Fool
Enliven's CMO Sells 40,000 Shares for $1.2 Million
2d ago
Yahoo Finance
Terns Acquisition Sparks Hope for Enliven Therapeutics' Blood Cancer Pipeline
5d ago
stocktwits
ENLIVEN THERAPEUTICS INC: MIZUHO INCREASES TARGET PRICE FROM $41 TO $45
5d ago
moomoo
Enliven Therapeutics (ELVN.US) Officer Plans to Sell $3.08 Million in Common Stock via Form 144
6d ago
moomoo
Enliven Therapeutics Q4 Earnings Miss Expectations
Mar 03 2026
seekingalpha
Enliven Therapeutics Executive Sells 20,000 Shares
Feb 01 2026
Fool
Enliven Therapeutics COO Anish Patel Sells 48,300 Shares for $1,351,000
Jan 13 2026
Yahoo Finance
Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology
Jan 12 2026
Newsfilter
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
Jan 09 2026
Benzinga
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Enliven Therapeutics Reports Promising Phase 1b Data for ELVN-001 in CML Patients
Jan 08 2026
Benzinga
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction
Jan 08 2026
Benzinga
Neogen Corp (NEOG) Reports Q2 Earnings Beat, Shares Surge 28%
Jan 08 2026
Benzinga
Acuity Inc. Reports 20.2% Revenue Growth in Q1 2026
Jan 08 2026
Benzinga
Show More News
